GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Galderma Group AG (FRA:PY30) » Definitions » LT-Debt-to-Total-Asset

Galderma Group AG (FRA:PY30) LT-Debt-to-Total-Asset : 0.22 (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Galderma Group AG LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Galderma Group AG's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.22.

Galderma Group AG's long-term debt to total assets ratio declined from Dec. 2023 (0.39) to Dec. 2024 (0.22). It may suggest that Galderma Group AG is progressively becoming less dependent on debt to grow their business.


Galderma Group AG LT-Debt-to-Total-Asset Historical Data

The historical data trend for Galderma Group AG's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galderma Group AG LT-Debt-to-Total-Asset Chart

Galderma Group AG Annual Data
Trend Dec23 Dec24
LT-Debt-to-Total-Asset
0.39 0.22

Galderma Group AG Semi-Annual Data
Jun23 Dec23 Jun24 Dec24
LT-Debt-to-Total-Asset - 0.39 0.23 0.22

Galderma Group AG LT-Debt-to-Total-Asset Calculation

Galderma Group AG's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )/Total Assets (A: Dec. 2024 )
=2601.42/12049.235
=0.22

Galderma Group AG's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )/Total Assets (Q: Dec. 2024 )
=2601.42/12049.235
=0.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Galderma Group AG  (FRA:PY30) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


Galderma Group AG LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Galderma Group AG's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Galderma Group AG Business Description

Traded in Other Exchanges
Address
Zahlerweg 10, Zug, CHE, 6300
Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a standalone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 45% of net sales from the US and employs around 6,600 people.

Galderma Group AG Headlines

No Headlines